In this interview we discuss recent trials that looked at the use of upfront chemotherapy combined with androgen deprivation therapy in men with metastatic prostate cancer and how they have changed clinical practice.
This article will describe the historic background of Ra-223; outline the clinical studies which led to phase III trials of this agent; highlight key results of these phase III studies; and explore possible future directions for use of Ra-223 and other alpha particles—both in prostate cancer and for management of other diseases.
In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
Nancy Dawson, MD discusses PSA dynamics: the significance of PSA levels and PSA doubling time—the marker which currently provides the most information—and their usefulness in predicting metastatic disease and in counseling patients on their prognosis.